MN HF284

Requires insulin manufacturers to report wholesale acquisition costs to the Minnesota Commissioner of Health by September 1, 2019, with optional supporting documentation on pricing, net average prices, market competition, and cost-effectiveness.

Authorizes the Commissioner of Health to review reported insulin costs and determine if appropriate utilization creates "excess costs" (costs unsustainable to public and private health care systems over a ten-year period) by considering factors including product pricing, price concessions, therapeutic alternatives, patient access impacts, and manufacturer research/marketing costs.

Establishes a maximum reimbursement level if excess costs are found, capping manufacturer net profit margin at 50 percent and allowing the commissioner to determine remuneration for all supply chain participants; entities obtaining manufacturer price concessions below the maximum rate are not considered noncompliant.

Permits the Commissioner to convene an advisory work group with expertise in health care costs, medicine, pharmaceuticals, and patient perspectives; requires work group members to disclose conflicts of interest.

Requires the Office of the Attorney General to provide compliance guidance and pursue remedies for noncompliance with reimbursement rates; allows manufacturers to appeal commissioner decisions within 30 days, with appeals subject to judicial review under chapter 14.